Peter Buhl Jensen

Directeur Général chez CHOSA ONCOLOGY AB

Profil

Peter Buhl Jensen founded Topotarget A in 2000, where he worked as Chief Executive Officer from 2000 to 2010, Oncology Venture Sweden AB in 2012, where he worked as Chief Executive Officer, Allarity Therapeutics A in 2004, where he worked as Chief Executive Officer & Director from 2012 to 2019, and Allarity Therapeutics Europe ApS in 2012, where he worked as Chairman & Chief Executive Officer.
Dr. Jensen also founded Chosa ApS and Buhl Oncology ApS.
Dr. Jensen also currently works at Symbion A, as Chief Executive Officer & Director from 2010, AntiAnthra ApS, as Chief Executive Officer from 2012, Chosa Oncology AB, as Chief Executive Officer from 2022, Medical Prognosis Institute, Inc., as Chairman, Amniotics AB, as Chairman from 2021, Symbion Fonden, as Director, Cobis A, as Director, the University of Copenhagen, as Professor from 2012, and Buhl Krone Holding ApS, as Owner.
Dr. Jensen also formerly worked at Medical Prognosis Institute A, as Chief Executive Officer & Director, Liplasome Pharma ApS, as Chief Executive Officer, Rigshospitalet, as Chief Executive Officer-Oncology Department from 2000 to 2008, Cytoguide ApS, as Chairman, Ranger Biotechnologies A, as Chairman, Affibody AB, as Director, LiPlasome Pharma A, as Director in 2012, Symbion Management A, as Director, Aprea Therapeutics AB, as Director, Axelar AB, as Director, Wntresearch AB, as Director, Respiratorius AB, as Director, 4 Best Invest ApS, as Director, IT-Væksthus A, as Director, Egetis Therapeutics AB, as Director, Medicon Valley Alliance FMBA, as Director, Renovaro Biosciences Denmark ApS, as Director, Vecata Ejendomme A, as Director, Valerio Therapeutics SA, as Principal, Alborg Sygehus, as Chief Oncologist-Oncology Department, and Aalborg University Hospital, as Chief Executive-Oncology Department.
Dr. Jensen received his doctorate degree from the University of Copenhagen.

Postes actifs de Peter Buhl Jensen

Sociétés	Poste	Début
AMNIOTICS AB	Président	15/04/2021
CHOSA ONCOLOGY AB	Directeur Général	01/03/2022
Buhl Krone Holding ApS	Corporate Officer/Principal	-
Medical Prognosis Institute, Inc.	Président	-
Symbion Fonden	Directeur/Membre du Conseil	-
Cobis A/S	Directeur/Membre du Conseil	-
AntiAnthra ApS	Directeur Général	01/01/2012
University of Copenhagen	Corporate Officer/Principal	07/03/2011
Symbion A/S	Directeur Général	01/01/2010

Anciens postes connus de Peter Buhl Jensen

Sociétés	Poste	Fin
░░░░░░░░ ░░░░░░░░░░░░ ░░░	░░░░░░░░░	░░░░░░░░░░
░░░░░░░░░░ ░░░	░░░░░░░░░ ░░░░░░░░░	░░░░░░░░░░
░░░░░░░░░ ░░░	░░░░░░░░░░	-
░░░░░░░ ░░░░░░ ░░░░░░░░ ░░░░	░░░░░░░░░░░░░░░░ ░░ ░░░░░░░	-
░░░░░░░░░░░░░░	░░░░░░░░░ ░░░░░░░░░░░░░░░░░	░░░░░░░░░░